Impel Pharmaceuticals

91 articles about Impel Pharmaceuticals

• Impel Pharmaceuticals Announces Exploration of Strategic Alternatives

  10/5/2023

  Impel Pharmaceuticals Inc. today announced that it has initiated an exploration of strategic alternatives.

• Impel Pharmaceuticals to Present New Real-World Data for Trudhesa® at the 65th Annual Scientific Meeting of the American Headache Society

  6/15/2023

  Impel Pharmaceuticals announced it will present new real-world data adding to the growing body of evidence supporting Trudhesa® nasal spray as an effective acute therapy for migraine management.

• Impel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update

  5/12/2023

  Impel Pharmaceuticals Inc. (NASDAQ: IMPL) today reported financial results for the first quarter ended March 31, 2023 and provided a business update.

• Impel Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer

  5/10/2023

  Impel Pharmaceuticals today announced the appointment of Michael W. Kalb, CPA, as Chief Financial Officer, effective May 10, 2023.

• Impel Pharmaceuticals to Report First Quarter 2023 Financial Results on Friday, May 12, 2023

  5/5/2023

  Impel Pharmaceuticals Inc. announced it will host a live webcast on Friday, May 12, 2023, at 8:30 a.m. ET to report its first quarter 2023 financial results and provide a business update.

• Impel Pharmaceuticals Presents New Data at AAN 2023 Suggesting Trudhesa® Nasal Spray is Safe to Use When Co-Administered With Commonly Prescribed Migraine Medications

  4/26/2023

  Impel Pharmaceuticals (NASDAQ: IMPL) today presented results from the first-ever pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of potential drug-drug interactions (DDIs) between Trudhesa® (dihydroergotamine [DHE] mesylate) nasal spray (0.725 mg per spray) and orally administered gepant medications.

• Impel Pharmaceuticals Announces Appointment of Darren Cline to the Board of DirectorsH. Stewart Parker Departing from Board

  4/12/2023

  Impel Pharmaceuticals, a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, announced the appointment of Darren Cline to the Board of Directors.

• Impel Pharmaceuticals to Present Data on Trudhesa® Nasal Spray for Treatment of Acute Migraine at 2023 American Academy of Neurology Annual Meeting

  4/11/2023

  Impel Pharmaceuticals announced that four Trudhesa® nasal spray abstracts have been selected to be presented at the upcoming American Academy of Neurology Annual Meeting taking place in Boston, MA, April 22-27, 2023.

• Impel Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

  3/24/2023

  Impel Pharmaceuticals Inc. today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update.

• Impel Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 24, 2023

  3/17/2023

  Impel Pharmaceuticals Inc. today announced it will host a live webcast on Friday, March 24, 2023, at 8:30 a.m. ET to report its fourth quarter and full year 2022 financial results and provide a business update.

• Impel Pharmaceuticals to Participate in Upcoming Investor Conferences in March 2023

  3/3/2023

  Impel Pharmaceuticals Inc., a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, announced that the Company will participate in two upcoming investor conferences in March.

• Impel Pharmaceuticals Announces Strategic Reprioritization, Continues Focus on Maximizing Trudhesa® Commercial Opportunity

  2/22/2023

  Impel Pharmaceuticals announced that it will implement an operational streamlining plan that will include a reduction of employee and non-employee expenses, largely impacting the research and development functions of the organization.

• Impel Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Corporate Update

  11/14/2022

  Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.

• Impel Pharmaceuticals to Participate in Guggenheim 4th Annual Immunology and Neurology Day

  11/8/2022

  Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced that the Adrian Adams, Chairman and Chief Executive Officer, will participate in a fireside chat at the Guggenheim 4th Annual Immunology and Neurology Day on Tuesday, November 15, 2022 at 1:00 p.m. ET in New York, NY.

• Impel Pharmaceuticals to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

  11/7/2022

  Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will host a live webcast on Monday, November 14, 2022, at 8:30 a.m. ET to report its third quarter 2022 financial results and provide a business update.

• Impel Pharmaceuticals to Participate in Upcoming Investor Conferences in September 2022

  9/6/2022

  Impel Pharmaceuticals Inc. announced that the Company will participate in two upcoming investor conferences in September.

• Impel Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Corporate Update

  8/15/2022

  Impel Pharmaceuticals today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.

• Impel Pharmaceuticals to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022

  8/8/2022

  Impel Pharmaceuticals Inc. today announced it will host a live webcast on Monday, August 15, 2022, at 8:30 a.m. ET to report its second quarter 2022 financial results and provide a business update.

• Impel Pharmaceuticals to Participate in 2022 Wedbush PacGrow Healthcare Conference

  8/2/2022

  Impel Pharmaceuticals Inc. today announced that Adrian Adams, Chairman and Chief Executive Officer, and John Leaman, M.D., Chief Financial and Business Officer, will participate in a fireside chat at the 2022 Wedbush PacGrow Healthcare Conference.

• Impel NeuroPharma to Ring Nasdaq Closing Bell on Monday, April 25

  4/21/2022

  Impel NeuroPharma announced that Chairman of the Board and Chief Executive Officer, Adrian Adams will ring the Nasdaq Stock Market closing bell on Monday, April 25, 2022.